Ben van Hout

Ben van Hout publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Ben van Hout sits on this spectrum.

Ben van Hout D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Ben van Hout sits on this spectrum.

Best Publications

• Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

  Ben Van Hout;M. F. Janssen;You-Shan Feng;Thomas Kohlmann

  2158
  Citations

• Valuing health-related quality of life: An EQ-5D-5L value set for England.

  Nancy J. Devlin;Koonal K. Shah;Yan Feng;Brendan Mulhern;Brendan Mulhern

  1421
  Citations

• Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients Insights From the Arterial Revascularization Therapy Study (ARTS) Trial

  Alexandre Abizaid;Marco A. Costa;Marinella Centemero;Andrea S. Abizaid

  477
  Citations

• A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol

  Mark Oppe;Nancy J. Devlin;Ben van Hout;Paul F.M. Krabbe

  460
  Citations

• Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery

  David J. Cohen;Ben Van Hout;Patrick W. Serruys;Friedrich W. Mohr

  337
  Citations

• Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.

  Elly Stolk;Kristina Ludwig;Kim Rand;Ben van Hout

  332
  Citations

• International Regulations and Recommendations for Utility Data for Health Technology Assessment

  Donna Rowen;Ismail Azzabi Zouraq;Helene Chevrou-Severac;Ben van Hout

  192
  Citations

• Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

  Gregg C. Fonarow;Anthony C. Keech;Terje R. Pedersen;Robert P. Giugliano

  166
  Citations

• Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

  Philippe Beutels;W. John Edmunds;Fernando Antoñanzas;G. Ardine De Wit

  129
  Citations

• A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale:

  Donna Rowen;John Brazier;Ben Van Hout

  123
  Citations

• Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

  Shravanthi R. Gandra;Guillermo Villa;Gregg C. Fonarow;Mickael Lothgren

  106
  Citations

• Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.

  Brendan Mulhern;Yan Feng;Koonal Shah;Mathieu F Janssen

  103
  Citations

• Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL and DEMQOL-Proxy

  Donna Rowen;Brendan Mulhern;Sube Banerjee;Ben van Hout

  99
  Citations

• Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

  Gerd Laux;Bart M. S. Heeg;Ben A. van Hout;Angelika Mehnert

  92
  Citations

• Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease

  Gregg C. Fonarow;Ben van Hout;Guillermo Villa;Jorge Arellano

  89
  Citations

• New methods for modelling EQ-5D-5L value sets: An application to English data.

  Yan Feng;Nancy J. Devlin;Koonal K. Shah;Brendan Mulhern;Brendan Mulhern

  86
  Citations

• Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.

  Maiwenn J Al;Talitha L Feenstra;Ben A van Hout

  81
  Citations

• A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO

  Nancy Devlin;Ken Buckingham;Koonal Shah;Aki Tsuchiya

  77
  Citations

• Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

  P. S. Chue;Bart M. S. Heeg;Erik Buskens;Ben A. van Hout

  72
  Citations

• Economic outcomes of percutaneous coronary intervention with drug‐eluting stents versus bypass surgery for patients with left main or three‐vessel coronary artery disease: One‐year results from the SYNTAX trial

  David J. Cohen;Tara A. Lavelle;Ben Van Hout;Haiyan Li

  70
  Citations